Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0249 Transporter Info | ||||
| Gene Name | SLC29A3 | ||||
| Protein Name | Equilibrative nucleoside transporter 3 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs780668 | ||||
| Site of GPD | chr10:71351651 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | T=0.4798/2403 (Global) | ||||
| Allele C | Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total | ||||
| Gemcitabine | Drug Info | Non-Small-Cell Lung Carcinoma | Irrelevant to the neutropenia and thrombocytopenia risk in patients (compare with Allele T) | [ 1] | |
| Gemcitabine | N.A. | Neutropenia | Allele C is not associated with risk of Neutropenia and Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T. | [ 1] | |
| Gemcitabine | N.A. | Thrombocytopenia | Allele C is not associated with risk of Neutropenia and Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T. | [ 1] | |
| Gemcitabine | N.A. | Non-small Cell Lung Carcinoma | Allele C is not associated with risk of Neutropenia and Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T. | [ 1] | |
| Genotypes CT + TT | Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total | ||||
| Gemcitabine | Drug Info | Non-Small-Cell Lung Carcinoma | Correlated with the increased overall survival in patients (compare with genotype CC); Irrelevant to the progression-free survival in patients (compare with genotype CC) | [ 1] | |
| Gemcitabine | N.A. | Overall Survival | Genotypes CT + TT are associated with increased overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC. | [ 1] | |
| Gemcitabine | N.A. | Progression-free Survival | Genotypes CT + TT are not associated with progression-free survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC. | [ 1] | |
| Gemcitabine | N.A. | Non-small Cell Lung Carcinoma | Genotypes CT + TT are not associated with progression-free survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC. | [ 1] | |
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Gemcitabine | N.A. | Non-small Cell Lung Carcinoma | Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have shorter overall survival as compared to patients with the CT and TT genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine. | [ 1] | |
| Genotype CT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Gemcitabine | N.A. | Non-small Cell Lung Carcinoma | Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine. | [ 1] | |
| Genotype TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Gemcitabine | N.A. | Non-small Cell Lung Carcinoma | Patients with the TT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine. | [ 1] | |
| References | |||||
| 1 | Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC Cancer. 2018 May 11;18(1):555. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.